M M Regan

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
    Meredith M Regan
    Meredith M Regan and Richard D Gelber, Dana Farber Cancer Institute, Harvard Medical School Karen N Price and Richard D Gelber, Frontier Science and Technology Research Foundation Richard D Gelber, Harvard T H Chan School of Public Health, Boston, MA Prudence A Francis, MacCallum Cancer Center, St Vincent s Hospital, University of Melbourne, Melbourne University of Newcastle, Newcastle Alan S Coates, University of Sydney, Sydney, Australia Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland Gini F Fleming, University of Chicago Medical Center, Chicago, IL Barbara A Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada Giuseppe Viale, University of Milan Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy István Láng, National Institute of Oncology, Budapest, 105 E Fourth St
    J Clin Oncol 34:2221-31. 2016
  2. pmc Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
    Meredith M Regan
    Department of Biostatistics and Computational Biology, International Breast Cancer Study Group Statistical Center, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mailstop CLS 11007, Boston, MA, 02215, USA
    Breast Cancer Res Treat 154:275-86. 2015
  3. pmc Predicting benefit of endocrine therapy for early breast cancer
    Meredith M Regan
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA Harvard Medical School, Boston, MA, USA Electronic address
    Breast 24:S129-31. 2015
  4. pmc Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Dana Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA Electronic address
    Breast 22:1094-100. 2013
  5. pmc CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 104:441-51. 2012
  6. pmc Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 12:1101-8. 2011
  7. pmc Using clinical trial data to tailor adjuvant treatments for individual patients
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast 16:S98-104. 2007
  8. pmc Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
    M M Regan
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Ann Oncol 21:312-8. 2010
  9. doi request reprint Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
  10. ncbi request reprint Predicting response to systemic treatments: learning from the past to plan for the future
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Breast 14:582-93. 2005

Detail Information

Publications80

  1. pmc Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
    Meredith M Regan
    Meredith M Regan and Richard D Gelber, Dana Farber Cancer Institute, Harvard Medical School Karen N Price and Richard D Gelber, Frontier Science and Technology Research Foundation Richard D Gelber, Harvard T H Chan School of Public Health, Boston, MA Prudence A Francis, MacCallum Cancer Center, St Vincent s Hospital, University of Melbourne, Melbourne University of Newcastle, Newcastle Alan S Coates, University of Sydney, Sydney, Australia Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland Gini F Fleming, University of Chicago Medical Center, Chicago, IL Barbara A Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada Giuseppe Viale, University of Milan Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy István Láng, National Institute of Oncology, Budapest, 105 E Fourth St
    J Clin Oncol 34:2221-31. 2016
    ..We examined absolute treatment effect across a continuum of recurrence risk to individualize endocrine therapy decision making for premenopausal women with human epidermal growth factor receptor 2 (HER2) -negative disease...
  2. pmc Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
    Meredith M Regan
    Department of Biostatistics and Computational Biology, International Breast Cancer Study Group Statistical Center, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mailstop CLS 11007, Boston, MA, 02215, USA
    Breast Cancer Res Treat 154:275-86. 2015
    ....
  3. pmc Predicting benefit of endocrine therapy for early breast cancer
    Meredith M Regan
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA Harvard Medical School, Boston, MA, USA Electronic address
    Breast 24:S129-31. 2015
    ....
  4. pmc Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Dana Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Boston, MA, USA Electronic address
    Breast 22:1094-100. 2013
    ..early breast cancer: 1-What is the role of aromatase inhibitors (AI) for women treated with ovarian function suppression (OFS)? 2-What is the role of OFS for women who remain premenopausal and are treated with tamoxifen?..
  5. pmc CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 104:441-51. 2012
    ..Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms...
  6. pmc Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 12:1101-8. 2011
    ..Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up...
  7. pmc Using clinical trial data to tailor adjuvant treatments for individual patients
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast 16:S98-104. 2007
    ..Overview analyses, joint analyses, the STEPP (subpopulation treatment effect pattern plot) method and recursive partitioning are valuable tools...
  8. pmc Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
    M M Regan
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Ann Oncol 21:312-8. 2010
    ..We investigated whether there is a subset of patients with CRPC for whom the efficacy of combination taxane-estramustine-carboplatin (TEC) chemotherapy may be greatest...
  9. doi request reprint Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
    ..PERCHE closed with inadequate accrual; TEXT accrued rapidly...
  10. ncbi request reprint Predicting response to systemic treatments: learning from the past to plan for the future
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Breast 14:582-93. 2005
    ..All findings from clinical trials and meta-analyses should be presented primarily according to steroid hormone receptor status and future studies should be designed as tailored treatment investigations...
  11. ncbi request reprint Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays
    Meredith M Regan
    IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Natl Cancer Inst 98:1571-81. 2006
    ..ER-positive premenopausal patients required further study...
  12. pmc Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Breast Cancer Res 13:209. 2011
    ..Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. Clinicaltrials.gov ID: NCT00004205...
  13. pmc Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
    Anita Giobbie-Hurder
    International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Trials 6:272-87. 2009
    ..Aromatase inhibitors provide superior disease control when compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer...
  14. pmc Phase II study of sunitinib in men with advanced prostate cancer
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Oncol 20:913-20. 2009
    ..This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC)...
  15. ncbi request reprint Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy
    Timothy J Daskivich
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 70:527-31. 2007
    ..To investigate whether the prostate-specific antigen doubling time (PSADT) and velocity (PSAV) at the emergence of androgen-independent prostate cancer (AIPC) provide independent prognostic information...
  16. ncbi request reprint Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer
    Daniel J George
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Urology 63:327-32. 2004
    ..To measure the change in plasma vascular endothelial growth factor (VEGF) levels after radical prostatectomy (RP) and to examine the association of pre-RP VEGF levels with known prognostic factors...
  17. ncbi request reprint Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
    M H Tay
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 15:974-8. 2004
    ..Effective, less toxic therapies are needed. This study examined whether the addition of finasteride to high-dose bicalutamide enhanced disease control, as measured by additional decreases in serum prostate-specific antigen (PSA)...
  18. ncbi request reprint Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase
    Wanling Xie
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 110:2709-15. 2007
    ..In the current study, the authors evaluated the combined effects of PSA and ALK-P on survival...
  19. ncbi request reprint Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:5408-13. 2006
    ..The purpose of this trial was to determine the feasibility, toxicity, and prostate-specific antigen (PSA) response of chemotherapy and limited ADT for men with PSA relapse...
  20. ncbi request reprint Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 107:975-81. 2006
    ..To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC...
  21. doi request reprint Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  22. doi request reprint Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 105:1392-6. 2010
    ....
  23. ncbi request reprint Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC)
    M Taplin
    Dana Farber Cancer Institute, Boston, MA Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada Oregon Health and Science University, Portland, OR Johns Hopkins, Baltimore, MD University of Texas M D Anderson Cancer Center, Houston, TX Beth Isreal Deaconess Medical Center, Boston, MA
    J Clin Oncol 26:5068. 2008
    ..Based on these observations, we conducted a single-arm phase II trial to assess combination therapy with KH and dutasteride (D) (KHAD), a dual type 1 and type 2 5α-reductase inhibitor, in CRPC...
  24. ncbi request reprint Quantitative gene expression at the 8q24 prostate cancer risk locus
    M Pomerantz
    Dana Farber Cancer Institute, Boston, MA Brigham and Women s Hospital, Boston, MA Broad Institute of Harvard and Massachussets Institute of Technology, Cambridge, MA
    J Clin Oncol 26:5055. 2008
    ..We sought to define the transcriptional landscape at 8q24 and identify the gene(s) influenced by the risk polymorphisms. More generally, we provide an approach for following up risk alleles from genome wide scans...
  25. pmc Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics
    R A Parker
    Biometrics Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 75:11234-8. 2001
    ..Thus, differences in VL variability over the course of infection and between viruses need to be considered when designing studies using the nonhuman primate AIDS models...
  26. ncbi request reprint Gender bias in the disposition of frozen embryos
    S Klipstein
    Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Fertil Steril 76:1181-4. 2001
    ..To examine the gender differences found among couples when choosing the disposition of their frozen embryos...
  27. ncbi request reprint Likelihood models for clustered binary and continuous outcomes: application to developmental toxicology
    M M Regan
    Biometrics Center E GZ 800, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Biometrics 55:760-8. 1999
    ..The joint risk of malformation and low birth weight can then be estimated directly. This approach is particularly well suited to estimating safe dose levels as part of quantitative risk assessment...
  28. ncbi request reprint Regression models and risk estimation for mixed discrete and continuous outcomes in developmental toxicology
    M M Regan
    Biometrics Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Risk Anal 20:363-76. 2000
    ..Dose-response models and their application to quantitative risk assessment are illustrated using data from a recent developmental toxicology experiment of ethylene oxide in mice...
  29. doi request reprint Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
    ..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)...
  30. doi request reprint Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 32:181-5. 2009
    ..The assumption that IL-2 therapy can be safely administered after TKI therapy may not be valid. Further examination of the safety of this sequential approach is necessary and more cautious patient selection seems warranted...
  31. doi request reprint Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
    ..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases...
  32. pmc Physicians' experiences with BRCA1/2 testing in community settings
    Nancy L Keating
    Division of General Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:5789-96. 2008
    ....
  33. pmc Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  34. doi request reprint Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ....
  35. ncbi request reprint Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials
    David F McDermott
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Genitourin Cancer 5:114-9. 2006
    ..This year, investigators will launch a clinical trial designed to prospectively determine whether patients who are more likely to respond to high-dose IL-2 can be identified before therapy is initiated...
  36. ncbi request reprint Association of cystic fibrosis with abnormalities in fatty acid metabolism
    Steven D Freedman
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 350:560-9. 2004
    ..In this study we determined whether humans with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have a similar fatty acid defect in tissues expressing CFTR...
  37. ncbi request reprint Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen
    Ignacio F San Francisco
    Division of Urologic Surgery and Biometrics Center MMR, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Urol 171:1492-9. 2004
    ..We examined the prognostic significance of clinical and pathological variables on outcome following radical retropubic prostatectomy (RRP) in a cohort of patients in the post-prostate specific antigen (PSA) era...
  38. ncbi request reprint Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis
    Sunil Sheth
    Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School, Dana 532, 330 Brookline Avenue, Boston, MA 02215, USA
    Hum Genet 113:286-92. 2003
    ....
  39. ncbi request reprint Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:2171-9. 2003
    ..This is important as randomized trials using chemotherapy are proposed. The authors used a questionnaire to investigate the attitudes of physicians in the New England area who care for patients with advanced prostate carcinoma...
  40. ncbi request reprint Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors
    Sharon L Bober
    David B Perini Quality of Life Clinic, D321, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 22:4951-7. 2004
    ..To explore the health-related and psychological factors that influence decision making about tamoxifen (Nolvadex; AstraZeneca, Waltham, MA) chemoprevention in women at increased risk for developing breast cancer...
  41. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  42. ncbi request reprint Cancer-related communication between female patients and male partners scale: A pilot study
    Alice B Kornblith
    Women s Cancers Program D 1210, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Psychooncology 15:780-94. 2006
    ....
  43. ncbi request reprint Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer
    Alice B Kornblith
    Breast Oncology Program Mayer 2, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Psychooncology 16:895-903. 2007
    ..The study's objective was to test whether there were signfiicant differences in adjustment between younger and older breast and endometrial cancer survivors...
  44. ncbi request reprint Effect of a germline polymorphism in the manganese superoxide dismutase (MnSOD) gene on the association of clinically aggressive prostate cancer with plasma selenium levels
    W Xie
    Dana Farber Cancer Institute, Boston, MA University of California San Francisco Cancer Center, San Francisco, CA
    J Clin Oncol 26:5057. 2008
    ..We further explore interaction between this polymorphism, plasma selenium levels and clinically aggressive prostate cancer...
  45. ncbi request reprint Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 96:783-6. 2005
    ....
  46. ncbi request reprint Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer
    Ignacio F San Francisco
    Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Urol 175:1341-5; discussion 1345-6. 2006
    ..We determined the relationship between age adjusted free T, and stage, grade and the biochemical-free survival rate in patients with surgically treated prostate cancer...
  47. ncbi request reprint Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy
    Glenn J Bubley
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 168:2249-52. 2002
    ..In fact, it is possible that altered levels of these proteins observed in subjects at risk for prostate cancer are the result of prostate cancer rather than related to its cause...
  48. ncbi request reprint Elevated plasma TIMP-1 and survival in metastatic castration-resistant prostate cancer patients
    W K Oh
    Dana Farber Cancer Institute, Boston, MA Penn State University, Hershey Medical Center, Hershey, PA Oncogene Science, Siemens Medical Diagnostics, Cambridge, MA Lebanon VA Medical Center, Lebanon, PA
    J Clin Oncol 26:11077. 2008
    ..Increased TIMP-1 has been associated with an unfavorable prognosis in multiple cancers...
  49. ncbi request reprint ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer
    M Bouzyk
    School of Medicine, Emory University, Atlanta, GA IBCSG Statistical Center, Boston, MA Dana Farber Cancer Institute, Boston, MA Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland Emory Biomarker Service Center, Atlanta, GA IBCSG Central Pathology Office, Milan, Italy IBCSG Coordinating Center, Bern, Switzerland European Institute of Oncology, Milan, Italy Kantonsspital St Gallen, St Gallen, Switzerland National Institute of Oncology, Budapest, Hungary University of Southern Denmark, Odense, Denmark Odense University Hospital, Odense, Denmark UZ Leuven, Leuven, Belgium Institute Bergonie, Bordeaux, France University of Sydney, Sydney, Australia Emory University, Atlanta, GA
    J Clin Oncol 29:1002. 2011
    ..We investigated if SNPs in ESR1 and ESR2 genes predict outcome and side effects of adjuvant endocrine therapies...
  50. ncbi request reprint Association between serum adiponectin and prostate cancer risk
    S Jacobus
    Dana Farber Cancer Institute, Boston, MA Harvard Radiation Oncology Program, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA
    J Clin Oncol 26:5147. 2008
    ..Recent studies have suggested a relationship between serum adiponectin and hormone-dependent prostate cancer (PCA), supported in part by an association between BMI and prostate cancer grade. We evaluated this potential relationship...
  51. ncbi request reprint Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve disease
    A D Maslow
    Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 34:2096-104. 1999
    ..To determine predictors of systolic anterior motion and left ventricular outflow tract obstruction (SAM/LVOTO) after mitral valve repair (MVRep) in patients with myxomatous mitral valve disease...
  52. ncbi request reprint Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer J 13:125-9. 2007
    ..However, little is known about the efficacy of VRL as second-line chemotherapy in HRPC...
  53. ncbi request reprint The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection
    Jean O Ung
    Department of Urologic Surgery and Biometrics Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Urol 169:130-5. 2003
    ..We investigated the relationship between prostate volume and cancer detection by needle biopsy, and determined the effect of an increased number of cores on the sampling error of needle biopsy on large prostate glands...
  54. ncbi request reprint Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients
    Dimitrios Spentzos
    Divisions of Hematology Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 9:3282-7. 2003
    ..The primary end point was PSA reduction by 50%. Secondary end points were PSA doubling time and time to progression (TTP). Serum was analyzed for changes in the sex hormone and insulin-like growth factor (IGF-I) axes...
  55. pmc Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4706-11. 2009
    ..We sought to determine the prevalence of TMPRSS2-ERG gene fusion among prostate-specific antigen-screened men undergoing prostate biopsy in the United States...
  56. pmc Evaluation of the 8q24 prostate cancer risk locus and MYC expression
    Mark M Pomerantz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 69:5568-74. 2009
    ..These data will help to direct the future study of this risk locus...
  57. doi request reprint Relationship between serum adiponectin and prostate cancer grade
    David J Sher
    Harvard Radiation Oncology Program, Boston, Massachusetts 02115, USA
    Prostate 68:1592-8. 2008
    ..We evaluated the relationship between serum adiponectin and Gleason score (GS) in a prospective series of patients seen in a single institution...
  58. ncbi request reprint Analysis of cystic fibrosis gener product (CFTR) function in patients with pancreas divisum and recurrent acute pancreatitis
    Andres Gelrud
    Division of Gastroenterology and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 99:1557-62. 2004
    ..The aim of this study was to determine if CFTR function is abnormal in patients with pancreas divisum and recurrent acute pancreatitis (PD/RAP)...
  59. pmc Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered
    Munir M Zaman
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Diagn Lab Immunol 11:819-24. 2004
    ..This is not a result of increased LPS receptor expression but, rather, is associated with alterations in MAPK signaling...
  60. ncbi request reprint Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy
    T K Choueiri
    Dana Farber Cancer Institute, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 26:16042. 2008
    ..We attempted to validate the prognostic and predictive utility of CAIX expression and previously defined pathologic features in pts treated with VEGF-targeted therapy...
  61. ncbi request reprint Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer
    M Nakabayashi
    Dana Farber Cancer Institute, Boston, MA Dana Farber Cancer Institute Harvard Medical School, Boston, MA Beth Israel Deaconess Medical Center, Boston, MA Dartmouth Hitchcock Medical Center, Lebanon, NH UMass Memorial Medical Center, Worcester, MA Dana Farber Cancer Instutute at Faulkner Hospital, Boston, MA
    J Clin Oncol 29:4657. 2011
    ..We previously reported the feasibility of chemotherapy and ADT for a cohort of 62 men with BR with a median follow-up (f/u) of 3.1 years (JCO 2006, 24:5408-13). We now report longer term f/u of this cohort...
  62. ncbi request reprint Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy
    T Schwarzberg
    Beth Israel Deaconess Medical Center, Boston, MA Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 26:5044. 2008
    ..We conducted a retrospective analysis of the tolerability and efficacy of IL-2 therapy in pts who had previously received anti-VEGF therapy...
  63. ncbi request reprint Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study
    D Y Heng
    Tom Baker Cancer Centre, Calgary, AB, Canada Dana Farber Cancer Institute, Boston, MA Cross Cancer Institute, Edmonton, AB, Canada Princess Margaret Hospital, Toronto, ON, Canada BC Cancer Agency, Vancouver, BC, Canada Beth Israel Deaconess Medical Center, Boston, MA Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
    J Clin Oncol 27:5041. 2009
    ..This study identifies PFs in this population and updated survival and validation results are presented...
  64. ncbi request reprint Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma
    A D Maslow
    Department of Anesthesia, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Anesthesiology 93:1198-204. 2000
    ....
  65. ncbi request reprint Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy
    I F San Francisco
    Division of Urologic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    BJU Int 92:924-8. 2003
    ....
  66. ncbi request reprint Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4
    Timothy J Daskivich
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 176:1927-37. 2006
    ..We then describe the need for methodological consistency with the literature by showing examples from our clinical experience at our institution...
  67. doi request reprint Absence of relationship between steroid hormone levels and prostate cancer tumor grade
    David J Sher
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Urology 73:356-61; discussion 361-2. 2009
    ..To analyze the relationship between plasma testosterone and estradiol levels on prostate biopsy and radical prostatectomy Gleason scores in a cohort of patients with newly diagnosed prostate cancer...
  68. pmc Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
    Qianben Wang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cell 138:245-56. 2009
    ..Thus, the role of AR in androgen-independent cancer cells is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth...
  69. doi request reprint Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection
    Stephen J Eyre
    Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 20015, USA
    J Urol 182:2653-8. 2009
    ..We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice...
  70. pmc 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC
    Nasim Ahmadiyeh
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
    Proc Natl Acad Sci U S A 107:9742-6. 2010
    ..We therefore propose that the 8q24 risk loci operate through a common mechanism-as tissue-specific enhancers of MYC...
  71. pmc The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
    Mark M Pomerantz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 41:882-4. 2009
    ..These data provide strong support for a biological mechanism underlying this non-protein-coding risk variant...
  72. pmc Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer
    Mary Ellen Taplin
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA
    Clin Cancer Res 15:7099-105. 2009
    ....
  73. doi request reprint Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  74. ncbi request reprint Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
    ..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer...
  75. doi request reprint Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
    ....
  76. ncbi request reprint Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
    Birgitte B Rasmussen
    Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
    Lancet Oncol 9:23-8. 2008
    ..Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours...
  77. ncbi request reprint Intravenously infused 13C-leucine is retained in fasting healthy adult men
    Anura V Kurpad
    Department of Physiology and Division of Nutrition, St John s Medical College, Bangalore, India
    J Nutr 132:1906-8. 2002
    ..We conclude that tracer leucine infused in the fasting state does not measurably increase leucine oxidation at the doses studied. Thus, tracer intake during the 12-h fast contributes to the effective leucine intake in 24-h DAAB studies...
  78. ncbi request reprint Lysine requirements of healthy adult Indian subjects receiving long-term feeding, measured with a 24-h indicator amino acid oxidation and balance technique
    Anura V Kurpad
    Department of Physiology and Nutrition Research Center, St John s Medical College, Bangalore, India
    Am J Clin Nutr 76:404-12. 2002
    ..The mean lysine requirement of healthy Indian subjects was estimated from short-term experimental diet periods to be 29 mg x kg(-1) x d(-1), which is higher than the 1985 FAO/WHO/UNU upper requirement of 12 mg x kg(-1) x d(-1)...
  79. pmc Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time
    Philip M Arlen
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 179:2181-5; discussion 2185-6. 2008
    ..It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting...
  80. ncbi request reprint Survey of breast-feeding practices and outcomes in the cystic fibrosis population
    Eliza M Parker
    Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, Massachusetts 01655, USA
    Pediatr Pulmonol 37:362-7. 2004
    ..This survey indicates that breast-feeding is not harmful to children with CF, and may be beneficial...